Bacillus calmette-guerin substrain tice live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bacillus calmette-guerin substrain tice live antigen
Accession Number
DB10343
Description

Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis for percutaneous use. It is administered to prevent the development of tuberculosis.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Synonyms
  • BCG, Live, Tice Strain

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Altretamine.
AmantadineThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Amantadine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Bcg VaccineInjection, powder, lyophilized, for solution50 mg/1PercutaneousOrganon USA Inc.1989-06-21Not applicableUs
OncoticePowder, for solutionIntravesicalMerck Ltd.1995-12-31Not applicableCanada
Tice BcgPowder, for suspension50 mg/50mLIntravesicalOrganon USA Inc.1990-08-24Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
2XQ558L16Z
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910522
RxNav
221050
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentCancer, Bladder1
3RecruitingTreatmentCancer, Bladder2
3RecruitingTreatmentHigh-risk Non-muscle Invasive Bladder Cancer1
3RecruitingTreatmentStage 0 Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Urothelial Carcinoma1
2Not Yet RecruitingSupportive CareBladder Urothelial Carcinoma In Situ / Recurrent Bladder Urothelial Carcinoma / Stage 0a Bladder Cancer AJCC v8 / Stage 0is Bladder Cancer AJCC v8 / Stage I Bladder Cancer AJCC v8 / Superficial Bladder Urothelial Carcinoma1
2, 3Not Yet RecruitingTreatmentCutaneous Metastatic Melanoma1
1CompletedTreatmentCancer, Bladder1
1CompletedTreatmentTransitional Cell Carcinoma of Bladder1
1RecruitingTreatmentRecurrent Bladder Carcinoma / Stage 0a Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Cancer1
1, 2Active Not RecruitingTreatmentCancer, Bladder1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionPercutaneous50 mg/1
Powder, for solutionIntravesical
Powder, for suspensionIntravesical50 mg/50mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 13:03 / Updated on August 10, 2020 08:11

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates